Gastrointestinal Cancer Archives - Insights https://news.mayocliniclabs.com/category/gastroenterology/gi-cancer/ Get the latest news and education from Mayo Clinic Laboratories Wed, 14 Aug 2024 18:46:22 +0000 en-US hourly 1 https://wordpress.org/?v=6.8.1 Targeted panel boosts accuracy of hereditary pancreatitis testing: Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C. https://news.mayocliniclabs.com/2024/03/26/targeted-panel-boosts-accuracy-of-hereditary-pancreatitis-testing-linda-hasadsri-m-d-ph-d-and-huong-t-cabral-m-s-cgs/ https://news.mayocliniclabs.com/2024/03/26/targeted-panel-boosts-accuracy-of-hereditary-pancreatitis-testing-linda-hasadsri-m-d-ph-d-and-huong-t-cabral-m-s-cgs/#respond Tue, 26 Mar 2024 13:00:00 +0000 https://news.mayocliniclabs.com/?p=109715 Targeted panel boosts accuracy of hereditary pancreatitis testing: Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C.Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C., explain how Mayo Clinic Laboratories' targeted test panel facilitates accurate diagnosis of hereditary pancreatitis, which heightens the risk for pancreatic cancer. Test results can guide cancer monitoring for patients and their families.

The post Targeted panel boosts accuracy of hereditary pancreatitis testing: Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C. appeared first on Insights.

]]> https://news.mayocliniclabs.com/2024/03/26/targeted-panel-boosts-accuracy-of-hereditary-pancreatitis-testing-linda-hasadsri-m-d-ph-d-and-huong-t-cabral-m-s-cgs/feed/ 0 A comprehensive test menu explores genome for druggable targets to treat gastrointestinal cancers https://news.mayocliniclabs.com/2024/03/13/a-comprehensive-test-menu-explores-genome-for-druggable-targets-to-treat-gastrointestinal-cancers/ https://news.mayocliniclabs.com/2024/03/13/a-comprehensive-test-menu-explores-genome-for-druggable-targets-to-treat-gastrointestinal-cancers/#respond Wed, 13 Mar 2024 13:00:00 +0000 https://news.mayocliniclabs.com/?p=109570 A comprehensive test menu explores genome for druggable targets to treat gastrointestinal cancersSince 1992, cases of colorectal cancer have been on a slow decline, yet 52,550 people died from it in 2023. At Mayo Clinic, a cutting-edge menu of both germline (inherited genetic alterations) and somatic (tumors due to non-inherited genetic alterations) testing are two critical tools helping to improve targeted treatments for colorectal and other common gastrointestinal cancers.

The post A comprehensive test menu explores genome for druggable targets to treat gastrointestinal cancers appeared first on Insights.

]]> https://news.mayocliniclabs.com/2024/03/13/a-comprehensive-test-menu-explores-genome-for-druggable-targets-to-treat-gastrointestinal-cancers/feed/ 0